Granted Patent
B2
US 12,516,091 · App. 16/264,896 · Granted Jan 6, 2026
Reelin compositions for treatment of neurological disorders
Assignee:
University of South Florida
C07K14/473A61K9/0019A61K35/761A61K38/1709A61K48/0066A61K48/0075A61K48/0083A61P25/28C12N15/113C12N15/62
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Changes in Reelin levels as well as Reelin signaling alter cognitive function. This can be accomplished by administering a therapeutically effective amount of a repeat fragment of Reelin, or a construct formed from fragment repeats of Reelin to a patient or subject. Changes to Reelin levels can be used to treat various neurodegenerative diseases, neuronal insults, or stroke, such as fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, and schizophrenia. Reelin can also be used to alter dendritic spine density, diminished long-term potentiation, and diminished synaptic plasticity and associative learning deficits. Constructs formed from repeat region 3 of full length Reelin and repeat region 5 of full length Reelin, or repeat region 3 of full length Reelin and repeat region 6 of full length Reelin have been found particularly useful.
Claims (11)
1 . A therapeutically effective amount of a viral vector composition encoding a Reelin recombinant protein fragment effective at inducing Reelin-dependent Apolipoprotein E Receptor (ApoER) activation and signaling, wherein the Reelin recombinant protein fragment is selected from:
Reelin fragment repeat R3 through R4,
Reelin fragment repeat R3 through R5,
Reelin fragment repeat R3 joined to Reelin fragment repeat R5 (SEQ ID NO: 11, or Reelin fragment repeat R3 joined to Reelin fragment repeat R6 (SEQ ID NO: 9); wherein
Reelin fragment repeat R3 is encoded by the nucleotide sequence consisting of SEQ ID NO: 2,
Reelin fragment repeat R4 is encoded by the nucleotide sequence consisting of SEQ ID NO: 3,
Reelin fragment repeat R5 is encoded by the nucleotide sequence consisting of SEQ ID NO: 4, and
Reelin fragment repeat R6 is encoded by the nucleotide sequence consisting of SEQ ID NO: 5; and wherein
a Loop Region encoded by a nucleotide sequence consisting of SEQ ID NO: 6 is disposed between Reelin fragment repeats R3 and R4, and
a Loop Region encoded by a nucleotide sequence consisting of SEQ ID NO: 7 is disposed between Reelin fragment repeats R4 and R5.
2 . The viral vector composition of claim 1 , wherein the viral vector is selected from the group consisting of AAV-9, AAV-5, AAV-4, and AAV-1.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 8, 2019
From: WEEBER, EDWIN J.
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 048276/0032 →
Continuity (4)
Continuation
PCTUS2017045307
· Aug 3, 2017
Provisional Application
62486729
· Apr 18, 2017
Provisional Application
62370519
· Aug 3, 2016
References Cited (166)
US 6323177B1
· Curran et al.
· 2001
[cited by applicant]
US 7341844B2
· Fatemi et al.
· 2008
[cited by applicant]
US 7682806B2
· Fatemi et al.
· 2010
[cited by applicant]
US 8912315B2
· Hirai et al.
· 2014
[cited by applicant]
US 9028825B2
· Hochstrasser et al.
· 2015
[cited by applicant]
US 9241975B2
· Weeber et al.
· 2016
[cited by applicant]
US 9890364B2
· Joung et al.
· 2018
[cited by applicant]
US 9962426B2
· Weeber
· 2018
[cited by examiner]
US 20020137095A1
· Mikoshiba et al.
· 2002
[cited by applicant]
US 20030165485A1
· Bertilsson et al.
· 2003
[cited by applicant]
US 20050196754A1
· Drmanac et al.
· 2005
[cited by applicant]
US 20060216292A1
· Hopf
· 2006
[cited by applicant]
US 20070141625A1
· Santos et al.
· 2007
[cited by applicant]
US 20080255163A1
· Sugaya et al.
· 2008
[cited by applicant]
US 20090215896A1
· Morseman et al.
· 2009
[cited by applicant]
US 20100100333A1
· Pi et al.
· 2010
[cited by applicant]
US 20100280760A1
· Pi et al.
· 2010
[cited by applicant]
US 20110016539A1
· Weinstein et al.
· 2011
[cited by applicant]
US 20110212060A1
· Hernandez et al.
· 2011
[cited by applicant]
US 20110213219A1
· Bilello et al.
· 2011
[cited by applicant]
US 20110311984A1
· Paek et al.
· 2011
[cited by applicant]
US 20130149237A1
· Dennis
· 2013
[cited by applicant]
US 20130184173A1
· Bar-Or et al.
· 2013
[cited by applicant]
US 20150183850A1
· Davidson et al.
· 2015
[cited by applicant]
US 20160265057A1
· Smith et al.
· 2016
[cited by applicant]
US 20190262401A1
· Schipper et al.
· 2019
[cited by applicant]
US 20200085838A1
· Martinez et al.
· 2020
[cited by applicant]
US 20200095280A1
· Ko et al.
· 2020
[cited by applicant]
US 20230054593A1
· Weeber
· 2023
[cited by examiner]
ES 2421207
· 2013
[cited by applicant]
JP 2014071016
· 2014
[cited by applicant]
JP 2015520161A
· 2015
[cited by applicant]
JP 2016503405A
· 2016
[cited by applicant]
RU 2012118224
· 2013
[cited by applicant]
WO 2010007063
· 2010
[cited by applicant]
WO WO2013172964A
· 2013
[cited by applicant]
WO 201427668
· 2014
[cited by applicant]
WO 2014131468
· 2014
[cited by applicant]
WO 201513148A2
· 2015
[cited by applicant]
WO 2016100575A1
· 2016
[cited by applicant]
WO 2019084338
· 2019
[cited by applicant]
Hethorn et al. Reelin supplementation recovers synaptic plasticity and cognitive deficits in a mouse model for Angelman syndrome. European Journal of Neuroscience, vol. 41, pp. 1372-1380, 2015 (Year: 2015).
[cited by examiner]
O'Connor et al. Gene therapy for neurodegenerative diseases. Trends in Molecular Medicine, Aug. 2015, vol. 21, No. 8 (Year: 2015).
[cited by examiner]
Jossin et al. (J Neurosci. Jan. 14, 2004; 24(2): 514-521). The Central Fragment of Reelin, Generated by Proteolytic Processing In Vivo, Is Critical to Its Function during Cortical Plate Development (Year: 2004).
[cited by examiner]
Pesold, et al., Cortical bitufted, horizontal and Martinotti cells preferentially express and secrete Reelin into berineuronal nets, non-synaptically modulating gene expression. Proc. Natl. Acad. Sci. USA. 1999; 96: 321…
[cited by applicant]
Hoe HS, Harris DC, Rebeck GW. Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem 2005;93:145-155.
[cited by applicant]
Hoe HS, Freeman J, Rebeck GW. Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons. Mol Neurodegener 2006, 1:18.
[cited by applicant]
Hoe HS, Pocivavsek A, Chakraborty G, et al. Apolipoprotein E receptor 2 interactions with the N-methyl-Daspartate receptor. J Biol Chem 2006, 281:3425-3431.
[cited by applicant]
Schmid, et al. Reelin, integrin and DAB1 interactions during embryonic cerebral cortical development. Cereb Cortex 2005, 15(10): 1632-1636.
[cited by applicant]
Kohno, et al., Mechanism and significance of specific proteolytic cleavage of Reelin. Biochem. Biophys. Res.Commun. 2009;380: 93-97.
[cited by applicant]
Dulabon, et al., Reelin binds alpha3beta1 integrin and inhibits neuronal migration. Neuron. 2000;27:33-44.
[cited by applicant]
Nakajima, et al., Disruption of hippocampal development in vivo by CR-50 mAb against reelin. Proc. Natl. Acad. Sci. U S A. 1997;94:8196-8201.
[cited by applicant]
De Bergeyck, et al., A truncated Reelin protein is produced but not secreted in the ‘Orleans’ reeler mutation (Reln[rl-Orl]). Brain Res. Mol. Brain Res. 1997;50:85-90.
[cited by applicant]
Saez-Valero, et al., Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer's disease. J. Neurosci. Res. 2003;72:132-136.
[cited by applicant]
Botella-López, et al. Reelin expression and glycosylation patterns arealtered in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 2006;103:5573-5578.
[cited by applicant]
Fatemi, et al., Altered levels of Reelin and its isoforms in schizophrenia and mood disorders. Neuroreport. 2001;12:3209-3215.
[cited by applicant]
Tinnes, et al., Epileptiform activity interferes with proteolytic processing of Reelin required for dentate granule cell positioning. FASEBJ. 2011;25:1002-1013.
[cited by applicant]
Tinnes, et al., TIMP-1 inhibits the proteolytic processing of Reelin in experimental epilepsy. FASEBJ. 2013;27:2542-2552.
[cited by applicant]
Kaneko, et al., Kainic acid-induced golgi complex fragmentation/dispersal shifts the proteolysis of reelin in primary rat heuronal cells: an in vitro model of early stage epilepsy. Mol. Neurobiol. 2016;53:1874-1883.
[cited by applicant]
Madhusudan, et al., Accumulation of reelin-positive plaques is accompanied by a decline in basal forebrain projection neurons during normal aging. Eur J Neurosci. 2009; 30:1064-1076.
[cited by applicant]
Knuesel, et al., Age-related accumulation of Reelin in amyloidlike deposits. Neurobiol Aging. 2009; 30:697-716.
[cited by applicant]
Jossin, et al., Reelin signals through phosphatidylinositol 3-kinase and Akt to control cortical development and through mTor to regulate dendritic growth. Mol Cell Biol. 2007; 27:7113-7124.
[cited by applicant]
Qiu, S., K. M. Korwek, A. R. Pratt-Davis, M. Peters, M. Y. Bergman, and E. J. Weeber. 2006. Cognitive disruption and altered hippocampus synaptic function in Reelin haploinsufficient mice. Neurobiol Learn Mem 85:228-242.
[cited by applicant]
International Search Report and Written Opinion issued by the International Searching Authority on Jan. 18, 2018 for corresponding International Patent Application No. PCT/US17/45307.
[cited by applicant]
International Preliminary Report on Patentability issued by the International Bureau on Feb. 14, 2019 for corresponding International Patent Application No. PCT/US17/45307.
[cited by applicant]
D'Arcangelo, G. et al. Reelin is a Ligand for Lipoprotein Receptors. Neuron, vol. 24, 471-479, Oct. 1999.
[cited by applicant]
Yasui, Norihisa, et al. “Structure of a receptor-binding fragment of reelin and mutational analysis reveal a recognition mechanism similar to endocytic receptors.” Proceedings of the National Academy of Sciences 104.24 …
[cited by applicant]
Patent Examination Report issued for New Zealand Application No. 750291, dated Jul. 27, 2020.
[cited by applicant]
Office Action and Substantive Examination Report issued for Saudi Arabia Application No. 519401017, dated Oct. 10, 2021.
[cited by applicant]
Office Action, dated Jul. 8, 2022, received in connection with corresponding EP Patent Application No. 17837688.5.
[cited by applicant]
Notice of Preliminary Rejection, dated Jun. 23, 2022, received in connection with correspoding KR Patent Application No. 10-2019-7006269 (English translation).
[cited by applicant]
Final Office Action, dated Jan. 21, 2022, received in connection with corresponding JP Patent Application No. 2019-505258 (English translation).
[cited by applicant]
DeSilva, U., et al., “Definition: reelin [
[cited by applicant]
Office Action issued in New Zealand Application No. 750291, dated Mar. 15, 2021.
[cited by applicant]
Deirdre M. O'connor et al: “Gene therapy for neurodegenerative diseases”, Trends in Molecular Medicine, vol. 21, Iss. 8, pp. 504-512.
[cited by applicant]
Office Action issued in Canadian Application No. 3,032,697, Dated Apr. 22, 2021.
[cited by applicant]
Office Action issued in European U.S. Application No. 17837688, dated Apr. 23, 2021.
[cited by applicant]
European Supplementary Search Report and Written Opinion issued for European U.S. Application No. 17837688, dated Apr. 2, 2020.
[cited by applicant]
Lussier, April L., Edwin J. Weeber, and G. William Rebeck. “Reelin proteolysis affects signaling related to normal synapse function and neurodegeneration.” Frontiers in cellular neuroscience 10 (2016): 75.
[cited by applicant]
Daily, Jennifer L., et al. “Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome.” PloS one 6.12 (2011).
[cited by applicant]
Ranaivoson, Fanomezana M., Sventja von Daake, and Davide Comoletti. “Structural insights into Reelin function: present and future.” Frontiers in cellular neuroscience 10 (2016): 1-8.
[cited by applicant]
Orcinha, C., Münzner, G., Gerlach, J., Kilias, A., Follo, M., Egert, U., & Haas, C. A. (2016). Seizure-induced motility of differentiated dentate granule cells is prevented by the central Reelin fragment. Frontiers in c…
[cited by applicant]
Guidotti, et al., Decrease in reelin and glutamic acid decarboxylase 67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen Psychiatry. 2000; 57: 1061-1069.
[cited by applicant]
Chen, et al., Identification of a single nucleotide polymorphism at the 5′ promoter region of human reelin gene and association study with schizophrenia. Mol. Psychiatry. 2002; 7: 447-448.
[cited by applicant]
Fatemi, et al., Reelin glycoprotein in autism and schizophrenia. Int. Rev. Neurobiol. 2005; 71: 179-187.
[cited by applicant]
Torrey, et al., Neurochemical markers for schizophrenia, bipolar disorder and major depression in postmortem brains. Biol. Psychiatry. 2005; 57: 252-26.
[cited by applicant]
Fatemi, et al., Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol. Psychiatry. 2000; 5: 654-663.
[cited by applicant]
Knable, et al., Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the stanley neuropathology consortium. Mol. Psychiatry. 2004; 9: 609-620.
[cited by applicant]
Lussier, et al., Repeated exposure to corticosterone, but not restraint, decreases the number of Reelin-positive cells in the adult rat hippocampus. Neurosci. Lett. 2009; 460: 170-174.
[cited by applicant]
Lussier, et al., Reelin as a putative vulnerability factor for depression: examining the depressogenic effects of repeated corticosterone in heterozygous reeler mice. Neuropharmacol. 2011; 60: 1064-1074.
[cited by applicant]
Lussier, et al., The progressive development of depression-like behavior in corticosterone-treated rats is paralleled by slowed granule cell maturation and decreased reelin expression in the adult dentate gyrus. Neuroph…
[cited by applicant]
Lussier, et al., Altered GABAergic and glutamatergic activity within the rat hippocampus and amygdala in rats subjected to repeated corticosterone administration but not restraint stress. Neurosci. 2013; 231: 38-48.
[cited by applicant]
Fenton, et al., Imipramine protects against the deleterious effects of chronic corticosterone on depression-like behavior, hippocampal reelin expression and neuronal maturation. Prog. Neuropsychopharmacol. Biol.Psychiat…
[cited by applicant]
Hoe, et al., DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor2 trafficking and processing. J. Biol Chem. 2006; 281: 35176-35185.
[cited by applicant]
Hoareau, et al., Amyloid precursor protein cytoplasmic domain antagonizes Reelin neurite outgrowth inhibition of hippocampal neurons. Neurobiol. Aging. 2008; 29: 542-553.
[cited by applicant]
Jossin, et al., The central fragment of Reelin, generated by proteolytic processing in vivo, is critical to its function during cortical plate development. J. Neurosci. 2004;24: 514-521.
[cited by applicant]
Jossin, et al., Processing of Reelin by embryonic neurons is important for function in tissue but not in dissociated cultured neurons. J. Neurosci. 2007;27: 4243-4252.
[cited by applicant]
Krstic, et al., Regulated proteolytic processing of Reelin through interplay of tissue plasminogen activator (tPA), ADAMTS-4, ADAMTS-5 and their modulators. PLoS One. 2012; 7:e47793.
[cited by applicant]
Trotter, et al., Extracellular proteolysis of reelin by tissue plasminogen activator following synaptic potentiation. Neuroscience. 2014; 274: 299-307.
[cited by applicant]
Nagy, et al., Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 2006;26: 1923-1934.
[cited by applicant]
Nogi, et al., Structure of a signaling-competent reelin fragment revealed by X-ray crystallography and electron tomography. EMBO J. 2006;25: 3675-3683.
[cited by applicant]
Nakano, et al., The extremely conserved C-terminal region of Reelin is not necessary for secretion but is required for efficient activation of downstream signaling. J. Biol Chem. 2007;282: 20544-20552.
[cited by applicant]
Hisanaga, et al., A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4) cleaves Reelin in an soform-dependent manner. FEBS Lett. 2012; 586: 3349-3353.
[cited by applicant]
D'Arcangelo, et al., Reelin is a secreted glycoprotein recognized by the CR-50 monoclonal antibody. J. Neurosci. 1997;17: 23-31.
[cited by applicant]
Sato, et al., Determination of cleavage site of Reelin between its sixth and seventh repeat and contribution of meprin metalloproteases to the cleavage. J. Biochem. 2016;159: 305-312.
[cited by applicant]
D'Arcangelo, et al., Reelin is a ligand for lipoprotein receptors. Neuron. 1999; 24: 471-479.
[cited by applicant]
Weeber, et al., Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J. Biol Chem. 2002; 277: 39944-39952.
[cited by applicant]
Herz & Chen, Reelin, lipoprotein receptors and synaptic plasticity. Nat. Rev Neurosci. 2006;7, 850-859.
[cited by applicant]
Niu, et al., Reelin promotes hippocampal dendrite development through the VLDLR/ApoER2-Dab1 pathway. Neuron. 2004; 41: 71-84.
[cited by applicant]
Beffert, et al. Modulation of synaptic plasticity and memory by Reelin involves differential splicing of the lipoprotein receptor Apoer2. Neuron. 2005; 47: 567-579.
[cited by applicant]
Chen, et al., Reelin modulates NMDA receptor activity in cortical neurons. J. Neurosci. 2005; 25, 8209-8216.
[cited by applicant]
Qiu, et al., Differential reelin-induced enhancement of NMDA and AMPA receptor activity in the adult hippocampus. J. Neurosci. 2006; 26: 12943-12955.
[cited by applicant]
Qiu & Weeber, Reelin signaling facilitates maturation of CA1 glutamatergic synapses. J. Neurophysiol. 2007;97: 2312- 2321.
[cited by applicant]
Burrell, et al., (2014). Fyn tyrosine kinase increases Apolipoprotein E recep tor 2 levels and phosphorylation. PLoS One 9:e110845.
[cited by applicant]
Divekar, et al., Ligand-induced homotypic and heterotypic clustering of Apolipoprotein E receptor 2. J. Biol Chem. 2014;289: 15894-15903.
[cited by applicant]
Niu, et al., The Reelin signaling pathway promotes dendritic spine development in hippocampal neurons. J. Neurosci. 2008; 28: 10339-10348.
[cited by applicant]
Rogers, et al., Reelin supplementation enhances cognitive ability, synaptic plasticity and dendritic spine density. Learn. Mem. 2011;18: 558-564.
[cited by applicant]
Rogers, et al. Reelin supplementation recovers sensorimotor gating, synaptic plasticity and associative learning deficits in the heterozygous reeler mouse. J. Psychopharmacol. 2013;27: 386-395.
[cited by applicant]
Beffert, et al., Reelin-mediated signaling locally regulates protein kinase B /Akt and glycogen synthase kinase 3 beta. J. Biol Chem. 2007;277: 49958-49964.
[cited by applicant]
Beffert, et al., Reelin and cyclin-dependent kinase 5-dependent signals cooperate in regulating neuronal migration and synaptic transmission. J. Neurosci. 2004;24:1897-1906.
[cited by applicant]
Chin, et al. Reelin depletion in the entorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease. J Neurosci 2007, 27:2727-2733.
[cited by applicant]
Miettinen, et al. Reelin-immunoreactivity in the hippocampal formation of 9-month-old wildtype mouse: effects of APP/PS1 genotype and ovariectomy. J Chem Neuroanat. 2005, 30:105-1180.
[cited by applicant]
Hethorn et al., Reelin supplementation recovers synaptic plasticity and cognitive deficits in a mouse model for Angelman syndrome. European Journal of Neuroscience, vol. 41, pp. 1372-1380, 2015.
[cited by applicant]
Howell, et al., Mouse disabled (mDab1): a Src binding protein implicated in neuronal development. EMBO J. 1997;16: 121-132.
[cited by applicant]
Hiesberger, et al., Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron. 1999; 24: 481-489.
[cited by applicant]
Strasser, et al., (2004). Receptor clustering is involved in Reelin signaling. Mol Cell Biol. 2004; 24: 1378-1386.
[cited by applicant]
Trotter, et al., Dab1 is required for synaptic plasticity and associative learning. J. Neurosci. 2013;33: 15652-15668.
[cited by applicant]
Ohkubo, et al. Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an Apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3beta cascae. The FASEB Journal express article published online D…
[cited by applicant]
Rogers & Weeber, Reelin and ApoE actions on signal transduction, synaptic function and memory formation. Neuron Glia Biol. 2008;4:259-270.
[cited by applicant]
Zhao, et al., Balance between neurogenesis and gliogenesis in the adult hippocampus: role for Reelin. Dev. Neurosci. 2007; 29: 84-90.
[cited by applicant]
Pujadas, et al., Reelin regulates postnatal neurogenesis and enhances spine hypertrophy and long-term potentiation. J. Neurosci. 2010;30: 4636-4649.doi.
[cited by applicant]
Teixeira, et al., Cell-autonomous inactivation of the Reelin pathway impairs adult neurogenesis in the hippocampus. J. Neurosci. 2012;32: 12051-12065.
[cited by applicant]
Notification of Reason(s) for Refusal in JP Patent No. 2019-505258. Jul. 13, 2021. 9 pages.
[cited by applicant]
Office Action issued for Canadian Application No. 3,032,697 dated May 20, 2020.
[cited by applicant]
Office Action issued for Colombian Application No. NC2019/0001060, dated May 13, 2020. .
[cited by applicant]
Genbank, “
[cited by applicant]
Office Action issued for Israeli Office Action dated Oct. 6, 2022.
[cited by applicant]
Office Action issued for Japanese Application No. 2019-505258, dated Oct. 12, 2022.
[cited by applicant]
Office Action ans Search Report issued for SA Application No. 519401017, dated Oct. 27, 2022.
[cited by applicant]
Office Action ans Search Report issued for Chinese Application No. dated Nov. 2, 2022.
[cited by applicant]
Koie, Mari, et al. “Cleavage within Reelin repeat 3 regulates the duration and range of the signaling activity of Reelin protein.” Journal of Biological Chemistry 289.18 (2014): 12922-12930.
[cited by applicant]
Australian Examination Report for Application No. AU2017306558, dated Sep. 11, 2023.
[cited by applicant]
Communication Pursuant to Article 94(3) EPC, issued for Application No. 17837688.5, dated Mar. 18, 2024.
[cited by applicant]
Chinese Office Action issued in corresponding Application No. 201780057526.5, dated Oct. 26, 2023.
[cited by applicant]
Brazilian Technical Requirement issued in corresponding Application No. BR112019002204-0, dated Nov. 16, 2023.
[cited by applicant]
Office Action for Indian Application No. 201947007585 dated Jan. 31, 2023, 8 pages.
[cited by applicant]
Office Action for Canadian Application No. 3,032,697 dated Feb. 13, 2023, 3 pages.
[cited by applicant]
Notice before Acceptance for Israeli Application No. 264603 dated Feb. 15, 2023, 3 pages.
[cited by applicant]
Decision for Grant for Korean Application No. 10-2019-7006269 dated Feb. 23, 2023, 3 pages.
[cited by applicant]
Decision to Grant for Japanese Application No. 2019-505258 dated Feb. 24, 2023, 5 pages.
[cited by applicant]
Gray, S. et al., ‘Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates’, The American Society of Gene & Cell Therapy', (Apr. 12, 2011), vol.…
[cited by applicant]
Korecka, J. et al., ‘Comparison of AAV Serotypes for Gene Delivery to Dopaminergic Neurones in the Substantia Nigra’, Viral Gene Therapy, (Jul. 20, 2011), doi: 10.5772/18939.
[cited by applicant]
Australian Examination Report issued for Application No. 2017306558, dated Aug. 19, 2024.
[cited by applicant]